The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 14
- 14 new
- Median first-year cost
- $321,583
- $4,311,937 in all
- Institutions
- 13
- 14 contact PIs
Awards by fiscal year
0
0
12
2
0
0
0
0
0
0
0
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- ALLEGHENY-SINGER RESEARCH INSTITUTE1
- BETH ISRAEL DEACONESS MEDICAL CENTER1
- COLLABORATIONS PHARMACEUTICALS, INC.1
- EMORY UNIVERSITY1
and 8 other institutions
Most frequent study sections
- Special Emphasis Panel (ZTR1 DPI-2 (01))13
- ZTR1-SRC(99)1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2017 | Application of a Repurposed FDA Approved Drug as a Local Osteogenic Agent1R21TR001751-01 | Sangadala, SreedharaWillett, Nick J | EMORY UNIVERSITY, GA | First-year cost $224,350 | Study section ZTR1 |
| FY2017 | Targeting glucose metabolism for the treatment of Hepatocellular Carcinoma1R21TR001743-01 | Chen, Bin | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | First-year cost $108,622 | Study section ZTR1 |
| FY2016 | Biomedical Data Translator Technical Feasibility Assessment and Architecture Design1OT3TR002020-01 | Ahalt, Stanley CarltonTropsha, Alexander | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | First-year cost $454,336 | Study section ZTR1 |
| FY2016 | Repurposing misoprostol for Clostridium difficile colitis as identified by PheWAS1R21TR001723-01 | Aronoff, David M | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | First-year cost $355,500 | Study section ZTR1 |
| FY2016 | Pre-clinical evaluation of a neutrophil elastase inhibitor for the treatment of inflammatory bowel disease1R21TR001753-01 | Kokkotou, Efi G. | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | First-year cost $346,000 | Study section ZTR1 |
| FY2016 | CXCR2 antagonism in the immunometabolic regulation of type 2 diabetes1R21TR001728-01 | Giannoukakis, Nick | ALLEGHENY-SINGER RESEARCH INSTITUTE, PA | First-year cost $341,528 | Study section ZTR1 |
| FY2016 | Network-driven drug repurposing approaches to treat coronary artery disease1R21TR001739-01 | Bjorkegren, Johan MGiannarelli, Chiara | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | First-year cost $339,000 | Study section ZTR1 |
| FY2016 | Anti-virulence drug repurposing using structural systems pharmacology1R21TR001722-01 | Xie, Lei | HUNTER COLLEGE, NY | First-year cost $328,384 | Study section ZTR1 |
| FY2016 | Quantum model repurposing of cethromycin for liver stage malaria1R21TR001737-01 | Sullivan, David Joseph | JOHNS HOPKINS UNIVERSITY, MD | First-year cost $326,166 | Study section ZTR1 |
| FY2016 | Drug Repositioning in Diabetic Nephropathy1R21TR001761-01 | Sarwal, Minnie M | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | First-year cost $317,000 | Study section ZTR1 |
| FY2016 | Repurposing lesogaberan for the treatment of type 1 diabetes1R21TR001742-01 | Kaufman, Daniel | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | First-year cost $308,000 | Study section ZTR1 |
| FY2016 | Ketorolac and Related NSAIDs for Targeting Rho-family GTPases in Ovarian Cancer1R21TR001731-01 | Wandinger-Ness, Angela | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | First-year cost $303,000 | Study section ZTR1 |
| FY2016 | Repurposing pyronaridine as a treatment for the Ebola virus1R21TR001718-01 | Davey, Robert AEkins, Sean | COLLABORATIONS PHARMACEUTICALS, INC., NC | First-year cost $288,801 | Study section ZTR1 |
| FY2016 | Therapeutic Repurposing of Benserazide for Colon Cancer1R21TR001734-01 | Szabo, Csaba | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | First-year cost $271,250 | Study section ZTR1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-16-0.3.5. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.